ZyVersa Therapeutics Ownership
| ZVSA Stock | 1.24 0.06 4.62% |
ZyVersa |
ZyVersa Stock Ownership Analysis
The company has Price to Book (P/B) ratio of 0.44. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. ZyVersa Therapeutics recorded earning per share (EPS) of 491.97. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 26th of April 2024. For more information please call the company at 754 231 1688 or visit https://www.zyversa.com.Besides selling stocks to institutional investors, ZyVersa Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different ZyVersa Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align ZyVersa Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
ZyVersa Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Less than 1% of ZyVersa Therapeutics are currently held by insiders. Unlike ZyVersa Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against ZyVersa Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of ZyVersa Therapeutics' insider trades
ZyVersa Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ZyVersa Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on ZyVersa Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ZyVersa Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
O'connor Daniel J. over two weeks ago Disposition of 23404 shares by Oconnor Daniel J. of ZyVersa Therapeutics subject to Rule 16b-3 | ||
Stephen Glover over two months ago Acquisition by Stephen Glover of 79417 shares of ZyVersa Therapeutics subject to Rule 16b-3 | ||
Briones David S. over two months ago Disposition of 57500 shares by Briones David S. of ZyVersa Therapeutics subject to Rule 16b-3 | ||
O'connor Daniel J. over two months ago Disposition of 23404 shares by Oconnor Daniel J. of ZyVersa Therapeutics subject to Rule 16b-3 | ||
O'connor Daniel J. over three months ago Acquisition by Oconnor Daniel J. of 1750 shares of ZyVersa Therapeutics subject to Rule 16b-3 | ||
Stephen Glover over six months ago Acquisition by Stephen Glover of 3022 shares of ZyVersa Therapeutics subject to Rule 16b-3 | ||
Labella Nicholas A. Jr. over six months ago Acquisition by Labella Nicholas A. Jr. of 59563 shares of ZyVersa Therapeutics subject to Rule 16b-3 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ZyVersa Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ZyVersa Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zyversa Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zyversa Therapeutics Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in ZyVersa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ZyVersa Therapeutics. If investors know ZyVersa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ZyVersa Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of ZyVersa Therapeutics is measured differently than its book value, which is the value of ZyVersa that is recorded on the company's balance sheet. Investors also form their own opinion of ZyVersa Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is ZyVersa Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ZyVersa Therapeutics' market value can be influenced by many factors that don't directly affect ZyVersa Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ZyVersa Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ZyVersa Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ZyVersa Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.